Grifols (NASDAQ:GRFS) Stock Rating Lowered by Zacks Research

Grifols (NASDAQ:GRFS) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Tuesday, Zacks reports.

Several other research firms have also weighed in on GRFS. Wall Street Zen lowered Grifols from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. Weiss Ratings raised Grifols from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, August 17th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Grifols from $10.00 to $9.00 and set a “neutral” rating for the company in a research note on Monday, October 26th. One research analyst has rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Grifols has an average rating of “Sell” and an average price target of $9.00.

Grifols Stock Performance

GRFS opened at $8.61 on Tuesday. Grifols has a 52-week low of $6.96 and a 52-week high of $9.77. The firm has a market capitalization of $5.86 billion, a PE ratio of 45.32, a PEG ratio of 0.33 and a beta of 0.75. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.81 and a current ratio of 2.33. The business’s 50-day simple moving average is $7.62 and its 200 day simple moving average is $8.00.

Institutional Investors Weigh In On Grifols

Several hedge funds have recently bought and sold shares of the company. Flat Footed LLC lifted its position in shares of Grifols by 26.5% in the first quarter. Flat Footed LLC now owns 1,372,394 shares of the biotechnology company’s stock valued at $11,007,000 after buying an additional 287,867 shares during the last quarter. Tidal Investments LLC increased its holdings in shares of Grifols by 9.8% during the 2nd quarter. Tidal Investments LLC now owns 1,233,082 shares of the biotechnology company’s stock worth $8,730,000 after acquiring an additional 109,612 shares during the last quarter. Royal Bank of Canada increased its holdings in shares of Grifols by 15.4% during the 1st quarter. Royal Bank of Canada now owns 785,703 shares of the biotechnology company’s stock worth $6,301,000 after acquiring an additional 104,850 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its stake in Grifols by 13.8% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 592,173 shares of the biotechnology company’s stock valued at $4,193,000 after acquiring an additional 72,037 shares during the period. Finally, Quantinno Capital Management LP raised its stake in Grifols by 42.0% in the 1st quarter. Quantinno Capital Management LP now owns 352,798 shares of the biotechnology company’s stock valued at $2,829,000 after acquiring an additional 104,418 shares during the period.

About Grifols

Grifols SA is a global healthcare company headquartered in Barcelona, Spain, specializing in plasma-derived medicines and diagnostic technologies. The company develops, manufactures and markets therapies made from human plasma, including immunoglobulins, albumin and coagulation factors used to treat immune deficiencies, bleeding disorders and other chronic conditions.

Grifols operates a vertically integrated plasma business that includes plasma donation centers, collection and fractionation facilities, research and development, manufacturing and distribution.